



OPEN ACCESS

EDITED AND REVIEWED BY
Jin Zhang,
University of Mississippi Medical
Center, United States

*CORRESPONDENCE
Jinghua Wu
wujh@ncst.edu.cn
Jinghua Zhang
jhzhang_te@163.com

SPECIALTY SECTION
This article was submitted to
Cancer Genetics,
a section of the journal
Frontiers in Oncology

RECEIVED 17 October 2022
ACCEPTED 31 October 2022
PUBLISHED 11 November 2022

CITATION
Su Y, Sai Y, Zhou L, Liu Z, Du P, Wu J
and Zhang J (2022) Corrigendum:
Current insights into the regulation of
programmed cell death by TP53
mutation in cancer.
Front. Oncol. 12:1071831.
doi: 10.3389/fonc.2022.1071831

COPYRIGHT
© 2022 Su, Sai, Zhou, Liu, Du, Wu and
Zhang. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s)
are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Current insights into the regulation of programmed cell death by TP53 mutation in cancer

Yali Su¹, Yingying Sai¹, Linfeng Zhou¹, Zeliang Liu²,
Panyan Du¹, Jinghua Wu^{1*} and Jinghua Zhang^{1*}

¹Department of Clinical Laboratory, North China University of Science and Technology Affiliated Tangshan Maternal and Child Health Care Hospital, Tangshan, China, ²Department of Clinical Laboratory, North China University of Science and Technology Affiliated Hospital, Tangshan, China

KEYWORDS

TP53 mutation, ferroptosis, pyroptosis, apoptosis, autophagic cell death, cancer

A Corrigendum on

Current insights into the regulation of programmed cell death by TP53 mutation in cancer

by Su Y, Sai Y, Zhou L, Liu Z, Du P, Wu J and Zhang J (2022) *Front. Oncol.* 12:1023427.
doi: 10.3389/fonc.2022.1023427

In the published article, there was an error in [Table 1](#) as published. The order of the references in [Table 1](#) was incorrect. The corrected [Table 1](#) appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

TABLE 1 Agents that target TP53 mutation.

Compound	Mechanism	References
PRIMA-1	restore the wild-type conformation to mutant P53 and induce apoptosis in cancer cells	(128)
APR-246(PRIMA-1 ^{Met})	restore the wild-type conformation to mutant P53 and induce apoptosis in cancer cells reduce glutathione(GSH) and thioredoxin reductase 1 (TXNRD1) increase ROS levels	(129) (130)
COTI-2	promote refolding of mutant p53 and restore wild-type-p53 function lead to activation of AMPK and inhibit the PI3K-AKT pathway	(124, 131)
MIRA1	restore transcriptional transactivation to mutant p53 in living cells	(132)
STIMA-1	preferentially kill mutant p53-carrying tumor cells activate caspases and induces Bax, PUMA and p21	(133)
Zinc metallochaperone-1 (ZMC1/NSC319726)	activate mutant p53 by restoring proper zinc loading decrease cellular GSH levels and increase ROS levels	(134, 135)
PK11007 and other similar compounds(PK11000,PK11010,PK11029,PK11003,PK11012 and PK11015)	alkylation of surface-exposed cysteines 182 and 277 and stabilized the p53 DBD without impairing its DNA-binding affinity increase protein and mRNA levels of the p21 and PUMA decrease cellular GSH levels and increase ROS levels	(126)
ReACp53 and related peptides(CDB3)	disrupts mutant-p53 aggregates and stabilise wild-type conformation	(136-138)
CP-31398	protect p53 from thermal degeneration,restore the wild type function of some mutant p53 and up-regulate p53 levels	(139, 140)
PhiKan083(PK083)	Binds to the DNA-binding domain of mutant-p53 and restore the wild type function of some mutant p53	(141-143)
RETRA	Treatment of mutant p53-expressing cancer cells with RETRA results in a substantial increase in the expression level of p73	(144)
PC14586	stabilize the Y220C mutant and restore p53 wild-type (normal) conformation	(145)
MDM2 Inhibitor : Nutlin-3 and ALRN-6924	Increase p53 levels and activity	(146, 147)
RG7388 and AMG232	disrupt the p53-MDM2 protein-protein interaction and prevent p53 from proteasomal degradation	(148, 149)

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.